Evoke Pharma to Present at LD Micro Conference SOLANA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Evoke Pharma to Present at LD Micro Conference

SOLANA BEACH, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK ), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Thursday, December 4, 2014 at 11:30AM PT at the LD Micro Main Event VII Conference. The conference is being held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

A copy of the corporate overview will be posted to the company's website following the presentation.

About Evoke Pharma, Inc.

Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com .

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the timing of top-line data completion of Evoke's ongoing Phase 3 clinical trial of EVK-001, the potential approval and commercialization of EVK-001 as a new and effective treatment for gastroparesis, the timing of top-line data completion of the thorough ECG study and Evoke's current trials and study serving as a basis for submission of a New Drug Application. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in Evoke's business, including, without limitation: Evoke is entirely dependent on the success of EVK-001, for which it has commenced a Phase 3 clinical trial, male companion trial and thorough ECG study, and Evoke cannot be certain that it will be able to obtain regulatory approval for, or successfully commercialize, EVK-001; the results observed in female patients with symptoms associated with acute and recurrent diabetic gastroparesis in Evoke's Phase 2b clinical trial of EVK-001 may not be predictive of the safety and efficacy results in the Phase 3 clinical trial; the risk that the results of the thorough ECG study may not replicate the cardiovascular safety profile observed in patients administered with metoclopramide to date; the inherent risks of clinical development of EVK-001, including potential delays in enrollment and completion of clinical trials and studies; Evoke will require substantial additional funding to complete the Phase 3 clinical trial of and potentially commercialize EVK-001 as well as to finance additional development requirements, and may be unable to raise capital when needed; the potential for adverse safety findings relating to EVK-001 to delay or prevent regulatory approval or commercialization; Evoke's reliance on outsourcing arrangements for many of its activities, including clinical development and supply of EVK-001; the ability of Evoke to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidate and the ability to operate its business without infringing the intellectual property rights of others; competition from other pharmaceutical or biotechnology companies; and other risks detailed in Evoke's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Contact: The Ruth Group David Burke Tel: 646-536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 57

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 65

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 135

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 113

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 75

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Update on Scully Royalty's Annual Meeting Plans

Updated Category News Views 129

Insightful Overview of Scully Royalty's Annual Meeting Scully Royalty Ltd. (NYSE: SRL) has recently provided valuable insights regarding its upcoming annual general meeting (AGM) scheduled for December 27, 2025. This update follows a noteworthy event involving MILFAM LLC, which filed a purported dissident proxy circular aimed at nominating five candidates for the...

Continue Reading
How a $1,000 Bitcoin Investment Shaped Financial Perspectives

Updated Category News Views 353

The Shift in Bitcoin's Investment Landscape Cryptocurrency has turned into a financial wild west, where fortunes are made and lost at lightning speed. At the center of this universe is Bitcoin, once brushed off by many traditional financiers. One such critic was Jamie Dimon, CEO of JPMorgan & Chase, who didn't hold back his disdain for the digital currency. Dimon’s...

Continue Reading
Netcompany's Share Buyback Program Progress Report

Updated Category News Views 162

Overview of Netcompany's Share Buyback Program In a strategic move to optimize its capital structure, Netcompany Group A/S has initiated a significant share buyback program aiming to repurchase up to DKK 250 million worth of shares. This action is accompanied by a target to acquire a maximum of 1,300,000 shares, reflecting Netcompany's commitment to fulfilling its...

Continue Reading
Ramaco Resources Partners with Goldman Sachs for Minerals Initiative

Updated Category News Views 133

Collaboration with Goldman Sachs Ramaco Resources, Inc. (NASDAQ: METC, METCB) has taken a significant step forward by teaming up with Goldman Sachs & Co. LLC. This partnership aims to establish a new initiative focused on creating a Strategic Critical Minerals Terminal (SCMT) at Ramaco's Brook Mine facility. Strategic Importance of the SCMT The SCMT initiative, approved...

Continue Reading
Understanding V2X's Upgrade to Buy: Key Insights Revealed

Updated Category News Views 96

Understanding V2X's Current Market Position V2X VVX has recently caught the eye of investors after being upgraded to a "Buy" rating. This upgrade marks a significant shift in earnings estimates, which are pivotal in determining stock valuations. The improved earnings outlook reflects a growing sense of optimism among analysts, boosting the overall attractiveness of the...

Continue Reading